Partnering for Hope 2015 ANNUAL REPORT
|
|
- Sherman Mason
- 5 years ago
- Views:
Transcription
1 Partnering for Hope 2015 ANNUAL REPORT
2 PATIENT CARE EVALUATION STUDY DISPARITIES IN THE MANAGEMENT OF ELDERLY BREAST CANCER PATIENTS Cynthia Osborne, MD, Mabel Mardones, MD, Janet Reynolds, CTR, Andrew Lupo, MS-IV Breast cancer is the most widespread cause of cancer among women in the United States. 1,2 In 2015, estimates of 231,840 new cases of invasive breast cancer will be diagnosed in women in the U.S., as well as an added 60,290 cases of in situ breast cancer. 1 Along with this high incidence of breast cancer, there is a high rate of death from breast cancer. In the U.S., estimates of 40,290 women will die from breast cancer in 2015, making it the second leading cause of death in women from cancer. 1 Worldwide, breast cancer was the leading cause of death in women in Breast cancer is a disease of aging. In the U.S., the median age of diagnosis of breast cancer is 61 but peaks in the 70s and then declines. The U.S. population is aging; from 2003 to 2013, the population of people aged 60, and above increased from 48.1 million to 62.8 million people, a rise of over 30%. 3 These numbers are expected to more than double by 2060 to 98 million people aged 60 or older. Analysis of the current data shows that older women are more numerous, with 25.1 million women to 19.6 million men, with a sex ratio of women for every 100 men. 3 By age 85 and over, this ratio increases to women for every 100 men. 3 As a result, women age 80 years and older are one of the fastest-growing segments of the U.S. population. s of death from breast cancer continue to increase as women age, leading to the statistic that 57% of all breast cancer deaths occur in women in the 65 years of age and older group. 1 Even with this high rate of death from breast cancer in older women, little is known about the characteristics of their cancer, treatment choices, or survival among this cohort. Some of this lack of data is due to the fact that historically few randomized controlled trials evaluating breast cancer treatments included women age 70 years or older, and most observational studies are limited by small sample size. In addition, increasing age is often accompanied by increasing comorbidity with associated reduction in physical conditioning, organ reserve, and cognitive and social functioning. Therefore, this leads to an inherent uncertainty as to the optimal approach in treating elderly women with breast cancer. This may negatively impact treatment options. Both observational studies and a randomized clinical trial, the TEAM trial which did not exclude women from participation based on age, have demonstrated several trends in older women with breast cancer. At presentation the tumor stage is higher, lower rates of breast conserving surgery with radiation are performed, and lower rates of
3 surgery and chemotherapy are administered as compared to younger breast cancer patients. 4 Additionally, while older women have been observed to die more frequently from all other causes, the risk of dying from breast cancer increases significantly with age. In order to better address the conundrums in treating this rapidly growing population of older women with breast cancer, we are evaluating patterns of care of elderly breast cancer populations as compared to younger patients treated in the Baylor Health Care System facilities from METHODS Using Baylor Health Care System Cancer Registry data, we identified all breast cancer cases seen throughout the system from Accessing the Texas Oncology iknowmed EMR, we then determined the type of surgery used in the general population by age. Other treatment trends that were included were frequency of breast conserving surgery with adjuvant radiation (BCS with XRT), radiation for patients with four or more positive lymph nodes, receipt of chemotherapy for hormone negative breast cancers, and receipt of hormone therapy for hormone positive breast cancers. Additionally, we evaluated the type of surgery performed in the early stage (I-II) breast cancer patients by age. Briefly, we followed the 2013 NCCN guidelines. 5 They are as follows: women who underwent a total mastectomy or lumpectomy and surgical axillary staging with four or more positive nodes are to have radiation therapy. Women with hormone receptor positive disease should have adjuvant endocrine therapy, while those with HER2 positive disease should receive adjuvant therapy with trastuzumab. Lastly, women with hormone receptor negative and HER2 negative disease should be treated with chemotherapy. Finally, one important point is that these guidelines do not take age into account. Thus, there are no specific guidelines for older women with breast cancer. RESULTS Breast Cancer Surgery We encountered a total of 4,933 surgeries of which 2,943 (59.7%) were mastectomies and 1,990 (40.3%) were breast conserving surgeries. In those patients 80 years of age and above, patients were split almost evenly between mastectomies (49.6%) and breast conserving surgery (50.4%). These rates were similar to those for women from 65 to 79 years of age (49.9% mastectomy and 50.0% for BCS). However, a greater percentage of women under the age of 65 had mastectomies (64.2%) compared to breast conserving surgery (35.8%). When the patients with early stage disease (stage I-II) were grouped by type of surgery and age, it was noted that women under 60 had more mastectomies; however, after the age of 60, this trend was reversed. Radiation therapy post Breast Conserving Surgery (BCS) When looking at the trends in radiation post BCS, we noted a steady decrease in the percentages of radiation-treated patients, particularly in those over the age of 80. Only 66% of patients received XRT in the 80 and over group, in comparison to 81 to 91% in those women under 40 years of age to 69. About 79% of patients from age 70 to 79 received radiotherapy, still greater than women 80 years of age and above. In those patients over the age of 80, 11% were not offered XRT and about 10% of patients in this category refused the therapy. Radiation treatment in women with four or more positive lymph nodes The trends in radiotherapy given to patients with breast cancer with four or more positive lymph nodes were consistently above 50% across all groups. There was, however, quite a bit of variability in the numbers. Levels of radiotherapy for four or more positive lymph nodes declined from a high of 77% for women under 40 to a low of 58% for women 60 to 69 years of age, while for patients from 70 to 79 years of age, this number spiked to 81%. Levels then dropped to 65% and 50% for women in the 80 to 89 and 90 and over group, respectively. Interestingly, at the same time these changes were seen in women treated with radiotherapy, the number of cases where radiotherapy was not recommended increased from 17% for women under 40 years of age up to 31% for women 60 to 69 years of age. Then this percentage of women who were not recommended therapy dropped to 2% in women 70 to 79 years of age. Therefore, this spike of 81% of women treated in the 70- to 79-yearold group may represent the fact that more women were recommended to undergo radiation treatment compared to the younger age groups.
4 The drop in radiation treatment in women over 80 may be due to the fact that a greater percentage of these patients refused treatment compared to any other age group. Chemotherapy for women with hormone negative breast cancers We noted a high incidence of chemotherapy given to all patients with hormone negative breast cancer who were less than 70 years of age. Above this threshold, there was a steep decline in patients treated with chemotherapy, with only 32% of women above the age of 80 being treated. In this group of older patients, a greater number of patients were not recommended or were contraindicated for chemotherapy treatment. This contraindication may be a result of patient comorbidities, such that physicians may have been concerned about treatment side effects. Endocrine therapy for hormone positive breast cancers There were a consistently high percentage of patients being offered hormone therapy across all age groups for women with hormone positive breast cancers. However, compared to women under 70 years of age, there still was a slight decrease in those women above the age of 70 and 80 (73% vs 74%), respectively, compared to younger women (79% to 84%). When the combination of endocrine therapy and radiotherapy was investigated by age, the results were mixed. In patients under 40 to 49 years of age, the percentage of patients who received hormone therapy with radiotherapy versus without radiotherapy was about 50/50. Beginning at age 50 to 59 years of age, there was a divergence, with more patients on hormone therapy getting radiotherapy versus those who did not receive radiotherapy. This difference was greatest for patients from 80 to 89 years of age (65.4% versus 34.7%, respectively). DISCUSSION In 2006, there were several studies that used the Surveillance, Epidemiology and End Results (SEER)-Medicare data set and examined the effectiveness of radiotherapy and chemotherapy among older women with breast cancer Results from numerous studies support the notion that older women are not treated according to the NCCN guidelines for breast cancer; however, the impact this has on breast cancer specific survival is controversial. 11 One study demonstrated the efficacy of surgery on survival of a small number of older breast cancer patients. 12 In a follow-up study using 369 patients aged 80 years or more, standard mastectomy was associated with a better breast cancer specific survival. 13 The complications after surgery for older breast cancer patients primarily involve slower wound healing, wound infection, and seromas. 14 In a study of older women with hormone receptor positive breast cancer, they found that patients could be divided into one of three groups; either patient declined, where the patient ruled out surgery, patient considered where the patient considered surgery but decided to undergo endocrine therapy instead, or surgeon declined where the surgeon decided the patient comorbidities were incompatible with surgery. 15 Thus, this group of patients is extremely diverse and both patients and surgeons may be more hesitant to decide that surgery is a viable option. In looking at our patients, about the same number underwent BCS versus mastectomy from age 70 on. This may be a selected group, as we did not include patients who did not have surgery, but our numbers are still high. We had 254 patients from 80 to 89 years of age who either had BCS or mastectomy. In our analysis, we note that women over 80 with breast cancer received less XRT post BCS, and for known indications, lower rates of systemic chemotherapy were being offered compared to their younger counterparts. We should note that in the 80 and older group there were higher contraindications for chemotherapy than in the younger breast cancer patients, indicating there may be more comorbidities present in these patients. These findings seem
5 to be in agreement with previously published trials. 7,11,16,17 Based on the results of our initial survey of patients treated at BHCS, we intend to compare women with early stage breast cancer outcomes into two groups; older and younger (>80 years of age and years of age). We will examine the impact of age on breast-related and other causes of death. Analysis will be performed within stage, adjusted for tumor characteristics, treatments received, and comorbidities. REFERENCES 1. Breast Cancer Facts & Figures Atlanta, American Cancer Society, Inc., Torre LA, Bray F, Siegel RL, et al.: Global cancer statistics, CA Cancer J Clin 65:87-108, A Profile of Older Americans: Washington, DC, Administration on Aging, Administration for Community Living, the US Department of Health and Human Services, Schonberg MA, Marcantonio ER, Li D, et al.: Breast cancer among the oldest old: tumor characteristics, treatment choices, and survival. J Clin Oncol 28: , Theriault RL, Carlson RW, Allred C, et al.: Breast cancer, version : featured updates to the NCCN guidelines. J Natl Compr Canc Netw 11:753-60; quiz 761, Elkin EB, Hurria A, Mitra N, et al.: Adjuvant chemotherapy and survival in older women with hormone receptornegative breast cancer: assessing outcome in a population-based, observational cohort. J Clin Oncol 24: , Giordano SH, Duan Z, Kuo YF, et al.: Use and outcomes of adjuvant chemotherapy in older women with breast cancer. J Clin Oncol 24:2750-6, Smith BD, Gross CP, Smith GL, et al.: Effectiveness of radiation therapy for older women with early breast cancer. J Natl Cancer Inst 98:681-90, Smith BD, Haffty BG, Buchholz TA, et al.: Effectiveness of radiation therapy in older women with ductal carcinoma in situ. J Natl Cancer Inst 98: , Smith BD, Haffty BG, Hurria A, et al.: Postmastectomy radiation and survival in older women with breast cancer. J Clin Oncol 24:4901-7, Owusu C, Lash TL, Silliman RA: Effect of undertreatment on the disparity in age-related breast cancer-specific survival among older women. Breast Cancer Res Treat 102:227-36, Cortadellas T, Gascon A, Cordoba O, et al.: Surgery improves breast cancer-specific survival in octogenarians with early-stage breast cancer. Int J Surg 11:554-7, Cortadellas T, Cordoba O, Gascon A, et al.: Surgery improves survival in elderly with breast cancer. A study of 465 patients in a single institution. Eur J Surg Oncol 41:635-40, Lavelle K, Sowerbutts AM, Bundred N, et al.: Pretreatment health measures and complications after surgical management of elderly women with breast cancer. Br J Surg 102:653-67, Sowerbutts AM, Griffiths J, Todd C, et al.: Why are older women not having surgery for breast cancer? A qualitative study. Psychooncology 24: , Gajdos C, Tartter PI, Bleiweiss IJ, et al.: The consequence of undertreating breast cancer in the elderly. J Am Coll Surg 192: , Yood MU, Owusu C, Buist DS, et al.: Mortality impact of less-than-standard therapy in older breast cancer patients. J Am Coll Surg 206:66-75, 2008 CANCER SCREENINGS BAYLOR SCOTT & WHITE MEDICAL CENTER FORT WORTH 2015 Screening Normal ABNORMAL Oral 92 4 Skin Cancer Low Dose CT Lung 126 Colonoscopies 1,868
6 CANCER REGISTRY NCDB Target CoC State of Texas CoC Census Region (West) All CoC Programs Baylor Scott & White Fort Worth Breast Cancer 2015 Forward Diagnosis Year 2011 (CoC) 2012* 2013* 2014* BCS: Breast Conservation surgery rate for women with AJCC clinical stage 0, I, or II breast cancer (Surveillance Measure) NbX: Image or palpation-guided needle biopsy (core or FNA) is performed for the treatment of breast cancer (Quality Improvement Measure) HT: Adjuvant Hormonal Therapy: Tamoxifen or third generation aromatase inhibitor is considered or administered within 1 year (365 days) of diagnosis for women with AJCC T1cNoMo, or Stage II or III hormone receptor positive breast cancer (Accountability Measure) MASTRT: Radiation therapy is considered or administered following any mastectomy within 1 year (365 days) of diagnosis for women with >= 4 positive lymph nodes (Accountability Measure) BCRST: Post Breast Conserving Surgery Irradiation: Radiation therapy is administered within 1 year (365 days) of diagnosis for women under age 70 and receiving breast conserving surgery for breast cancer (Accountability Measure) MACl: Adjuvant Chemotherapy: Combination chemotherapy is considered or administered within 4 months (120 days) of diagnosis for women under 70 with AJCC T1cNoMo, or Stage II or III hormone receptor negative breast cancer (Accountability Measure) NA 54.3% 57.0% 63.9% 37.7% 34.1% 36.5% 80.0% 73.2% 74.0% 76.4% 89.9% 94.6% 95.4% 90% 86.1% 87.1% 90.3% 95.2% 91.5% 93.1% 90.0% 56.6% 61.4% 71.7% 96.3% 93.8% 93.3% 90% 86.8% 88.6% 91.8% 93.9% 93.8% 98.2% 90% 90.0% 90.5% 92.5% 100.0% 89.3% 97.4% Colorectal Cancer ACT: Adjuvant Chemotherapy: Adjuvant chemotherapy is considered or administered within 4 months (120 days) of diagnosis to patients under age 80 with AJCC III (lymph node positive) colon cancer (Accountability Measure) 12 RLN: Surgical Resection Includes at Least 12 Lymph Nodes: At least 12 regional lymph nodes are removed and pathologically examined for resected colon cancer (Surveillance Measure) NA 88.5% 89.4% 90.6% 100.0% 100.0% 100.0% 85% 90.5% 89.0% 87.8% 92.3% 96.7% 82.7% Rectal Cancer RECRCT: Pre-operative chemo and radiation are administered for clinical AJCC T3N0, T4N0, or Stage III; or Postoperative chemo and radiation are administered within 180 days of diagnosis for clinical AJCC T1-2N0 with pathologic AJCC T3N0, T4N0, or Stage III; or treatment is considered, for patients under the age of 80 receiving resection for rectal cancer (Quality Improvement) 85% 66.7% 100.0% 100.0%
7 NCDB Target CoC State of Texas CoC Census Region (West) All CoC Programs Baylor Scott & White Fort Worth Gastric 2015 Forward Diagnosis Year 2011 (CoC) 2012* 2013* 2014* G15RLN: At least 15 regional lymph nodes are removed and pathologically examined for resected gastric cancer (Quality Improvement) 80% NA 33.3% NA Non Small Cell Lung 10RLN: At least 10 regional lymph nodes are removed and pathologically examined for AJCC Stage 1A, 1B, IIA, and IIB resected NSCLC (Surveillance Measure) NA 33.3% NA 0.0% LNoSurg: Surgery is not first course of treatment for cn2, M0 cases (Quality Improvement) 85% 100.0% 100.0% NA LCT: Systemic chemotherapy is considered or administered within 4 months to the day pre-operatively or day of surgery to 6 months postoperatively or surgically resected cases with pathologic lymph node positive (pn1) and (pn2) NSCLC (Quality Improvement) 85% NA NA NA Cervix CBRRT: Use of brachytherapy in patients treated with primary radiation with curative intent in any stage of cervical cancer (Surveillance Measure) CERRT: Radiation therapy completed within 60 days of initiation of radiation among women diagnosed with any stage of cervical cancer (Surveillance Measure) CERCT: Chemotherapy administered to cervical cancer patients who received radiation for Stages IB2-IV cancer (Group 1) or with positive pelvic nodes, positive surgical margin, and/or positive parametrium (Group 2) (Surveillance Measure) NA NA NA NA NA NA NA NA NA 100.0% 100.0% 100.0% Endometrium ENDLRC: Endoscopic, laparoscopic, or robotic performed for all endometrial cancer (excluding sarcoma and lymphoma), for all stages except Stage IV (Surveillance Measure) ENDCTRT: Chemotherapy and/or radiation administered to patients with Stage IIIC or IV Endometrial cancer (Surveillance Measure) NA 69.1% 80.6% 48.9% NA 60.0% 50.0% NA Ovary OVSAL: Salpingo-oophorectomy with omentectomy, debulking/cytoreductive surgery, or pelvic exteneration in Stages I-IIIC Ovarian Cancer (Surveillance Measure) NA 60.0% 63.6% 66.6% *Source: Data is pending results by the Rapid Quality Reporting Process via the National Cancer Data Base.
8 Photography may include models or actors and may not represent actual patients. Physicians provide clinical services as members of the medical staff at one of Baylor Scott & White Health s subsidiary, community or affiliated medical centers and do not provide clinical services as employees or agents of those medical centers, Baylor Health Care System, Scott & White Healthcare or Baylor Scott & White Health Baylor Scott & White Health. BID BHCSONC_
Partnering for Hope 2015 ANNUAL REPORT
Partnering for Hope 2015 ANNUAL REPORT PATIENT CARE EVALUATION STUDY DISPARITIES IN THE MANAGEMENT OF ELDERLY BREAST CANCER PATIENTS Cynthia Osborne, MD, Mabel Mardones, MD, Janet Reynolds, CTR, Andrew
More informationBringing the Fight to Cancer Annual Report
Bringing the Fight to Cancer. Annual Report Quality Study Improve process for breast biopsy patients to receive results of pathology reports Background A team from the Baylor Scott & White Medical Center
More informationBringing the Fight to Cancer Annual Report
Bringing the Fight to Cancer. 1 Annual Report Quality Study Adherence to Adjuvant Systemic Therapy Following Primary Surgery in Stage II Breast Cancer Patients: Baylor Scott & White Medical Center McKinney
More informationBringing the Fight to Cancer Annual Report
Bringing the Fight to Cancer. 216 Annual Report Quality Study Adherence to Adjuvant System Therapy Following Primary Surgery in Stage II Breast Cancer Patients: Baylor Scott & White Medical Center Irving
More informationBringing the Fight to Cancer Annual Report
Bringing the Fight to Cancer. Annual Report Quality Study Breast Imaging Scheduling Study of Quality Each year, based on the category, the quality improvement coordinator, under the direction of the Cancer
More informationBringing the Fight to Cancer Annual Report
Bringing the Fight to Cancer. 21 Annual Report Quality Study Adherence to Adjuvant Systemic Therapy Following Primary Surgery in Stage II Breast Cancer Patients: Baylor Scott & White Medical Center Grapevine
More informationBringing the Fight to Cancer Annual Report
Bringing the Fight to Cancer. 2016 Annual Report Identification of Disparity of Responsiveness Across Oncology Units at Baylor Scott & White Fort Worth Quality Study Improving Responsiveness of Staff for
More informationBCS HRH CoC St/% ACT HRH CoC St/% Endometrium CoC St/% ENDCTRT nbx 12RLN ENDLRC Mast RT Rec RT HRH 10 RLN BCS RT G15 RLN LCT MAC OVSAL LNoSurg
BCS HRH CoC St/% ACT HRH CoC St/% Endometrium CoC St/% 2010 86% n/a 2010 100% 90% ENDCTRT n/a 2011 69% 2011 100% 2010 100% 2012 96% 2012 100% 2013 90% 2013 100% 2012 no data nbx 12RLN 2010 85% 80% 2010
More informationCompassionate, team-driven cancer care CLOSE TO HOME.
Compassionate, team-driven cancer care CLOSE TO HOME. NATIONAL MEASURES FOR ACCOUNTABILITY AND QUALITY IMPROVEMENT The cancer program at OSF HealthCare Sacred Heart Medical Center is accredited by the
More informationExceptional cancer care, close to home.
Exceptional cancer care, close to home. SAINT JOSEPH HOSPITAL ELGIN The AMITA Health Saint Joseph Elgin Medical Center Cancer Program is accredited by the American College of Surgeons (ACoS) Commission
More informationPublic Reporting of Outcomes 2016
Public Reporting of Outcomes 2016 The Genesis Cancer Care Institute, Genesis Medical Center, Davenport, Iowa is an American College of Surgeon s Commission on Cancer (CoC) accredited program. The CoC is
More informationExceptional cancer care, close to home.
Exceptional cancer care, close to home. National Quality Performance Measures Presence Saint Joseph Hospital-Chicago and Presence Saint Francis joined forces in 2015 to become the Presence Lakeshore Region.
More informationCRStar E-News: Quality Measures
With the most recent upgrade to CRStar, six quality measures have been added. The user will now see all twelve quality measures in the dashboard reports under the RQRS title. The six new measures have
More information2015 Public Outcomes Report Cancer Program Practice Profile Reports 2013 Breast and Colon Cancer
As a Commission on Cancer (CoC)-accredited cancer program, HealthEast ensures that patients with cancer are treated according to nationally accepted measures. Measures for Quality of Cancer Care Each year,
More informationCOMMISSION ON CANCER 2013 Cancer Program Practice Profile Reports (CP 3 R)
COMMISSION ON CANCER 2013 Cancer Program Practice Profile Reports (CP 3 R) Women often choose to have a mastectomy with breast reconstruction surgery instead of breast conservation following a breast cancer
More information2016 CANCER PROGRAM REPORT. Bay Medical Sacred Heart Health System 615 North Bonita Avenue Panama City, FL
2016 CANCER PROGRAM REPORT Bay Medical Sacred Heart Health System 615 North Bonita Avenue Panama City, FL 32401 850.769.1511 www.baymedical.org 2016 Cancer Program Report Bay Medical Sacred Heart provides
More informationBreast Cancer Among the Oldest Old: Tumor Characteristics, Treatment Choices, and Survival
VOLUME 28 NUMBER 12 APRIL 20 2010 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Breast Cancer Among the Oldest Old: Tumor Characteristics, Treatment Choices, and Survival Mara A. Schonberg,
More information2018 PUBLIC REPORTING OF OUTCOMES
2018 PUBLIC REPORTING OF OUTCOMES The Cancer Committee at Western Maryland Health System s Schwab Family Cancer Center reports annually on program and patient outcomes in compliance with the accreditation
More informationOutcomes Q&A NAACCR Webinar Series July 7, 2016
Outcomes 2015-2016 NAACCR Webinar Series July 7, 2016 1 Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching this webinar at your
More informationDefining Safety and Quality Across the Cancer Care Continuum
Defining Safety and Quality Across the Cancer Care Continuum Defining Safety and Quality Across the Cancer Care Continuum April 28, 2016 Kristen Fessele, PhD, RN University of Utah Funding NINR T32NR013456
More informationCOMPREHENSIVE CANCER CENTER/DESERT REGIONAL MEDICAL CENTER 2017 COMMUNITY OUTREACH SUMMARY AND OUTCOMES REPORT
COMPREHENSIVE CANCER CENTER/DESERT REGIONAL MEDICAL CENTER 2017 COMMUNITY OUTREACH SUMMARY AND OUTCOMES REPORT The Health Assessment and Research for Communities (HARC) report, published in January 2017,
More informationQuality Measures: How we develop them and the science behind it
Quality Measures: How we develop them and the science behind it Matthew A Facktor MD FACS Geisinger Medical Center Danville PA Sandra L Wong MD MS FACS FASCO Dartmouth Hitchcock Medical Center Lebanon
More informationGeneral Information. Please silence cell phones. Locations Restrooms to the left of the ballroom, or to your right by the elevators
American American College College of of Surgeons 2013 Content 2014 Content cannot be be reproduced or or repurposed without written permission of of the the American College College of Surgeons. of Surgeons.
More informationCancer Program Report 2014
Cancer Program Report 2014 Queen of the Valley Hospital St Joseph Health Queen of the Valley Hospital - 2014 Site Table Site Total Class Sex Group Cases Analytic NonAn M F 0 I II ALL SITES 661 494 167
More informationCERVIX MEASURE SPECIFICATIONS
Cancer Programs Practice Profile Reports (CP 3 R) CERVIX MEASURE SPECIFICATIONS Introduction The Commission on Cancer s (CoC) National Cancer Data Base (NCDB) staff has undertaken an effort to improve
More informationCancer Endorsement Maintenance 2011-Maintenance Measures
Measure Number Title Description Measure Steward 0210 Proportion receiving chemotherapy in the last 14 days of life 0211 Proportion with more than one emergency room visit in the last days of life 0212
More informationFinancial Disclosure. Learning Objectives. Review and Impact of the NCDB PUF. Moderator: Sandra Wong, MD, MS, FACS, FASCO
Review and Impact of the NCDB PUF Moderator: Sandra Wong, MD, MS, FACS, FASCO Financial Disclosure I do not have personal financial relationships with any commercial interests Learning Objectives At the
More information2016 Public Reporting of Outcomes Standard 1.12
2016 Public Reporting of Outcomes Standard 1.12 Roland Matthews MD, Director GCCE Sheryl Gabram MD, Deputy Director GCCE Pooja Mishra FACHE, Executive Director GCCE Top 5 Primary Sites 250 200 150 100
More informationThe New CP 3 R Application And Revisions To Standard 4.6 Integration Of The NCDB With The Accreditation Process
The New CP 3 R Application And Revisions To Standard 4.6 Integration Of The NCDB With The Accreditation Process Wednesday, April 29, 2009 at 11 AM Central M. Asa Carter, CTR Manager, Approvals and Standards
More informationCancer Services 2018 Quality Report
Cancer Services 2018 Quality Report MAURY REGIONAL CANCER CENTER Clinical Excellence The Maury Regional Cancer Center is a comprehensive treatment center committed to medical excellence. We combine stringent
More informationOutcomes Report: Accountability Measures and Quality Improvements
Outcomes Report: Accountability Measures and Quality Improvements The s Cancer Committee ensures that patients with cancer are treated according to the nationally accepted measures. Because we are an accredited
More informationOutcomes Report: Accountability Measures and Quality Improvements
Outcomes Report: Accountability Measures and Quality Improvements The FH Memorial Medical Center s Cancer Committee ensures that patients with cancer are treated according to the nationally accepted measures.
More informationColorectal Cancer at the MemorialCare Todd Cancer Institute at Long Beach Memorial
Colorectal Cancer at the MemorialCare Todd Cancer Institute at Long Beach Memorial ANNUAL REPOR T (562) 933-0900 MemorialCare.org/TCI 2810 Long Beach Blvd. Long Beach, CA 90806 #3 Colorectal cancer is
More informationCancer Program ANNUAL REPORT
2 0 1 5 2015 Cancer Program ANNUAL REPORT 2015 Chairperson s Report HCGH Cancer Program Annual Report Reflecting back on what we have accomplished in HCGH s cancer program in 2015, we certainly have much
More informationQuiz. b. 4 High grade c. 9 Unknown
Quiz 1. 10/11/12 CT scan abdomen/pelvis: Metastatic liver disease with probable primary colon malignancy. 10/17/12 Colonoscopy with polypectomy: Adenocarcinoma of sigmoid colon measuring at least 6 mm
More informationA Year in Review. September 30 and October 1, 2017 were the dates for the expanded
December 29, 2017 Annual Report By any standard 2017 was an eventful year for the Cancer Centers of Southwest Oklahoma (CCSO). There were new clinical programs, the renewal of an important accreditation,
More informationPhysician Follow-Up and Guideline Adherence in Post- Treatment Surveillance of Colorectal Cancer
Physician Follow-Up and Guideline Adherence in Post- Treatment Surveillance of Colorectal Cancer Gabriela M. Vargas, MD Kristin M. Sheffield, PhD, Abhishek Parmar, MD, Yimei Han, MS, Kimberly M. Brown,
More informationRetrospective analysis to determine the use of tissue genomic analysis to predict the risk of recurrence in early stage invasive breast cancer.
Retrospective analysis to determine the use of tissue genomic analysis to predict the risk of recurrence in early stage invasive breast cancer. Goal of the study: 1.To assess whether patients at Truman
More information4/13/2010. Silverman, Buchanan Breast, 2003
Tailoring Breast Cancer Treatment: Has Personalized Medicine Arrived? Judith Luce, M.D. San Francisco General Hospital Avon Comprehensive Breast Care Center Outline First, treatment of DCIS Sorting risk
More informationNATIONAL QUALITY FORUM
Cancer Endorsement Maintenance Table of Submitted Measures Phase I 0210 1 Proportion receiving chemotherapy in the last 14 days of life Percentage of patients who died from cancer receiving chemotherapy
More informationSt. Vincent s Riverside Cancer Program Cancer Report
St. Vincent s Riverside Cancer Program 2018 Cancer Report 1 Table of Contents St. Vincent s Riverside Cancer Program... 1 Cancer Registry... 4 St. Vincent s Riverside Cancer Program practice profile report...
More informationLessons Learnt from Neoadjuvant Hormone Therapy. 10 Lessons Learnt from Neoadjuvant Endocrine Therapy. Lesson 1
Lessons Learnt from Neoadjuvant Hormone Therapy Mike Dixon Clinical Director Breakthrough Research Unit Edinburgh 10 Lessons Learnt from Neoadjuvant Endocrine Therapy 10 Lessons Learnt from Neoadjuvant
More informationLessons Learnt from Neoadjuvant Hormone Therapy. Mike Dixon Clinical Director Breakthrough Research Unit Edinburgh
Lessons Learnt from Neoadjuvant Hormone Therapy Mike Dixon Clinical Director Breakthrough Research Unit Edinburgh 10 Lessons Learnt from Neoadjuvant Endocrine Therapy 10 Lessons Learnt from Neoadjuvant
More informationOVARY MEASURE SPECIFICATIONS
Cancer Programs Practice Profile Reports (CP 3 R) OVARY MEASURE SPECIFICATIONS Introduction The Commission on Cancer s (CoC) National Cancer Data Base (NCDB) staff has undertaken an effort to improve the
More information!"#$ Oncology Outcomes Report
!"#$ Oncology Outcomes Report The Cleveland Clinic Florida Cancer Institute is dedicated to the comprehensive care of patients with cancer. Oncologists collaborate with a variety of physicians across multiple
More informationEvolution of CoC within ACoS. American College of Surgeons Commission on Cancer Current Activities and Future Initiatives November 5,2005
American College of Surgeons Commission on Cancer Current Activities and Future Initiatives November 5,25 FREDERICK L. GREENE, MD Chair, Commission on Cancer Evolution of CoC within ACoS Two plans proposed
More informationBreast cancer in octogenarian women: clinical characteristics and outcome
JBUON 2013; 18(2): 328-334 ISSN: 1107-0625 www.jbuon.com E-mail: info@jbuon.com ORIGINAL ARTICLE Breast cancer in octogenarian women: clinical characteristics and outcome T. Y. Kuzan 1, E. Koca 1, O. Dizdar
More informationShore Medical Center Site-Specific Study: Colorectal Cancer 2013
Shore Medical Center Site-Specific Study: Colorectal Cancer Shore Medical Center Site-Specific Study: Colorectal Cancer The following report is the result of a collaborative effort of four physician members
More informationBreast Cancer. Most common cancer among women in the US. 2nd leading cause of death in women. Mortality rates though have declined
Breast Cancer Most common cancer among women in the US 2nd leading cause of death in women Mortality rates though have declined 1 in 8 women will develop breast cancer Breast Cancer Breast cancer increases
More informationBreast Cancer. Saima Saeed MD
Breast Cancer Saima Saeed MD Breast Cancer Most common cancer among women in the US 2nd leading cause of death in women 1 in 8 women will develop breast cancer Incidence/mortality rates have declined Breast
More informationNeoadjuvant Treatment of. of Radiotherapy
Neoadjuvant Treatment of Breast Cancer: Role of Radiotherapy Neoadjuvant Chemotherapy Many new questions for radiation oncology? lack of path stage to guide indications should treatment response affect
More informationTools, Reports, and Resources
Tools, Reports, and Resources What the National Cancer Database (NCDB) does for CoC-Accredited Programs By using the NCDB, CoC-accredited programs can proactively improve delivery and quality of care for
More informationARROCase - April 2017
ARROCase - April 2017 Radiation Indications in the setting of Neoadjuvant chemotherapy for Breast Cancer Lauren Colbert, MD, MSCR Faculty Mentor: Benjamin Smith, MD UT MD Anderson Cancer Center 37 year
More informationMemorialCare Breast Center at Long Beach Memorial
MemorialCare Breast Center at Long Beach Memorial (562) 933-7880 MemorialCare.org/LBBreast Todd Cancer Pavilion, 2 nd Floor 2810 Long Beach Blvd. Long Beach, CA 90806 The Breast Center at the MemorialCare
More informationDAYS IN PANCREATIC CANCER
HOSPITAL AND MEDICAL CARE DAYS IN PANCREATIC CANCER Annals of Surgical Oncology, March 27, 2012 Casey B. Duncan, Kristin M. Sheffield, Daniel W. Branch, Yimei Han, Yong-Fang g Kuo, James S. Goodwin, Taylor
More informationSlide 1. Slide 2. Slide 3 History of Nurse Navigator
Slide 1 The Nurse Navigators role in Early Stage Breast Cancer, and Development of Tailored Treatment Plan Laura Ochoa, RN, ANP-BC, Ph.D. Slide 2 Barnes Jewish Hospital at Washington University Slide 3
More informationANNUAL REPORT. Figure 2 displays the distribution of the number of these diagnoses in 2013 by age (along the X axis) and by gender.
One ANNUAL REPORT Colorectal Cancer Colorectal cancer affects 14, Americans annually, making it the fourth most frequently diagnosed cancer in the US. It is also the second leading cause of cancer death
More informationOne Breast Cancer Annual Report
One 2015 Breast Cancer Annual Report One OVERVIEW The Breast Program at Carolinas HealthCare System s Levine Cancer Institute, offers comprehensive care. Patients with benign and malignant disease of the
More information2018 Quality and Outcomes Report
18 Quality and Outcomes Report TABLE OF CONTENTS Quality Review Quality Accreditations Quality Comparison Measures Quality Improvements 18 Community Outreach Activities and Outcomes Clinical Education
More informationQUALIFIED CLINICAL DATA REGISTRY (QCDR) 2017 MEASURE SPECIFICATIONS
QOPI5 Chemotherapy administered to patients with metastatic solid tumor with performance status of 3, 4, or undocumented (Lower Score - Better) Percentage of adult patients with metastatic solid tumors
More informationLeveraging Your Cancer Registry: A Strategy for Survey Success
CoC-trained consultants on staff Leveraging Your Cancer Registry: A Strategy for Survey Success Toni Hare, RHIT, CTR CoC-trained Consultant Vice President, CHAMPS Oncology November 27, 2012 Georgia s Best
More informationWhat is Cancer? Petra Ketterl, MD Medical Oncology and Functional Medicine
What is Cancer? Petra Ketterl, MD Medical Oncology and Functional Medicine What is Cancer? Layman s terms: cancer starts when cells grow out of control (in any place in the body) and crowd out normal cells
More informationMaking the Most of Your Cancer Registry
www.champsods.com Making the Most of Your Cancer Registry Presenter: Toni Hare, Vice President CHAMPS Oncology Data Services Picture of girl here December 11, 2009 Learning Objectives Upon completion of
More informationRadiation and DCIS. The 16 th Annual Conference on A Multidisciplinary Approach to Comprehensive Breast Care and Imaging
Radiation and DCIS The 16 th Annual Conference on A Multidisciplinary Approach to Comprehensive Breast Care and Imaging Einsley-Marie Janowski, MD, PhD Assistant Professor Department of Radiation Oncology
More informationBreast Cancer. Dr. Andres Wiernik 2017
Breast Cancer Dr. Andres Wiernik 2017 Agenda: The Facts! (Epidemiology/Risk Factors) Biological Classification/Phenotypes of Breast Cancer Treatment approach Local Systemic Agenda: The Facts! (Epidemiology/Risk
More informationChapter 2: Initial treatment for endometrial cancer (including histologic variant type)
Chapter 2: Initial treatment for endometrial cancer (including histologic variant type) CQ01 Which surgical techniques for hysterectomy are recommended for patients considered to be stage I preoperatively?
More informationCa in situ e ormonoterapia. Discussant : LORENZA MARINO
Ca in situ e ormonoterapia Discussant : LORENZA MARINO Ca in situ e ormonoterapia Quali fattori di rischio? Radioterapia? Ormonoterapia? BCS Recurrence rates (FUP 13-20y) Cuzick, Lancet Oncol.2011; 12(1):
More informationCancer Annual Report. Our story begins with you.
Cancer Annual Report 17 Our story begins with you. Chairman s message The Cancer Committee is formed under the direction of the Bylaws of the Medical Executive Committee and serves to monitor, supervise
More informationSo, Who are the appropriate individuals that should consider genetic counseling and genetic testing?
Hello, I m Banu Arun, Professor of Breast Medical Oncology and Co-Director of Clinical Cancer Genetics at the University of Texas MD Anderson Cancer Center. Today I will be discussing with you Hereditary
More informationData and Metrics for Evaluating and Improving Cancer Care Quality in Georgia
Data and Metrics for Evaluating and Improving Cancer Care Quality in Georgia Updates for GATRA on: 1) Augmenting GA Cancer Registry Data to Assess Adherence of Quality-of-Care Metrics 2) Commission on
More informationOncology Report to the Community. Northwestern Medicine Central DuPage Hospital and Northwestern Medicine Delnor Hospital
Oncology Report to the Community Northwestern Medicine Central DuPage Hospital and Northwestern Medicine Delnor Hospital 1 Contents Letter from Leadership.... 1 Survivorship: Life After Cancer Treatment....
More informationMeasure Definition Benchmark Endorsed By. Measure Definition Benchmark Endorsed By
Process Risk Assessment Tumor Site: Breast Process Presence or Risk absence Assessment of cancer in first-degree blood relatives documented in patients with invasive breast Presence cancer or absence of
More information2011 Physician Quality Reporting System Measures for Consideration by Oncology Providers: Cancer Care Measures
2011 Physician Quality Reporting System Measures for Consideration by Oncology Providers: Cancer Care Measures The table below includes measures directly relevant to oncology providers as well as general
More informationCancer Center Dashboard
Cancer Center Dashboard Measure Definition Benchmark Endorsed By Screening Breast Cancer Screening Percentage of eligible women 40-69 who received a mammogram within the past 24 months NCQA reported average:
More informationBreast Surgery: Yesterday, Today and Tomorrow
Breast Surgery: Yesterday, Today and Tomorrow Baptist Hospital Gladys L. Giron, MD, FACS October 11,2014 Homestead Hospital Baptist Children s Hospital Doctors Hospital Baptist Cardiac & Vascular Institute
More informationStage III Colon Cancer Susquehanna Cancer Center Warren L Robinson, MD, FACP May 9, 2007
Stage III Colon Cancer Susquehanna Cancer Center 1997-21 Warren L Robinson, MD, FACP May 9, 27 Stage III Colon Cancer Susquehanna Cancer Center 1997-21 Colorectal cancer is the third most common cancer
More informationColorectal Cancer Dashboard
Process Risk Assessment Presence or absence of cancer in first-degree blood relatives documented for patients with colorectal cancer Percent of patients with colorectal cancer for whom presence or absence
More informationCryoablation in the Management of Early Stage Breast Cancer
13 th Annual Pacific Northwest Breast and Gynecologic Care Conference Cryoablation in the Management of Early Stage Breast Cancer Dennis R. Holmes, M.D., Inc. Int. Director, Margie Peterson Breast Center
More information7/29/2014. Patterns of Care in Colon Cancer ( ) Literature. Background. Florida Cancer Data Compliance with NCCN Guidelines
Patterns of Care in Colon Cancer (21-212) Florida Cancer Data Compliance with FCDS Annual Meeting July 24-25, 214 Caribe Royale Resort Orlando, Florida Background O NCCN guidelines are referenced extensively
More informationWASHINGTON. Spokane Cheney. Olympia. Tri-Cities. Walla Walla. Portland North Central Oregon City OREGON. Mt. Vernon. Port Angeles
2 3 Mt. Vernon Port Angeles Bremerton Tacoma 5 5 Olympia Everett Edmonds Seattle 90 WASHINGTON 90 Spokane Cheney Pullman Longview 82 Tri-Cities Portland North Central Oregon City 5 84 OREGON Walla Walla
More informationPatient Identification Quiz
Patient Identification Quiz 1. A patient presents to your facility for the first time on 1/1/2009. At that time he has a history of lymphoma (9590/3), melanoma (8720/3) and meningioma (9530/0). These three
More informationSurgical Therapy: Sentinel Node Biopsy and Breast Conservation
Surgical Therapy: Sentinel Node Biopsy and Breast Conservation Stephen B. Edge, MD Professor of Surgery and Oncology Roswell Park Cancer Institute University at Buffalo Dr. Roswell Park: Tradition in Cancer
More informationIndex. Surg Oncol Clin N Am 16 (2007) Note: Page numbers of article titles are in boldface type.
Surg Oncol Clin N Am 16 (2007) 465 469 Index Note: Page numbers of article titles are in boldface type. A Adjuvant therapy, preoperative for gastric cancer, staging and, 339 B Breast cancer, metabolic
More informationBREAST CONSERVATION TREATMENT IN EARLY STAGE DISEASE AND DCIS LAWRENCE J. SOLIN, MD, FACR, FASTRO
BREAST CONSERVATION TREATMENT IN EARLY STAGE DISEASE AND DCIS LAWRENCE J. SOLIN, MD, FACR, FASTRO Chairman Department of Radiation Oncology Albert Einstein Healthcare Network Philadelphia, PA Professor
More informationPET/CT in breast cancer staging
PET/CT in breast cancer staging Anni Morsing Consultant, PhD, DMSc Rigshospitalet 1 18F- FDG PET/CT for breastcancer staging Where is the clinical impact? To which women should 18F- FDG PET/CT be offered?
More informationCase Scenario 1. 2/15/2011 The patient received IMRT 45 Gy at 1.8 Gy per fraction for 25 fractions.
Case Scenario 1 1/3/11 A 57 year old white female presents for her annual mammogram and is found to have a suspicious area of calcification, spread out over at least 4 centimeters. She is scheduled to
More informationInteractive Staging Bee
Interactive Staging Bee ROBIN BILLET, MA, CTR GA/SC REGIONAL CONFERENCE NOVEMBER 6, 2018? Clinical Staging includes any information obtained about the extent of cancer obtained before initiation of treatment
More informationPMRT for N1 breast cancer :CONS. Won Park, M.D., Ph.D Department of Radiation Oncology Samsung Medical Center
PMRT for N1 breast cancer :CONS Won Park, M.D., Ph.D Department of Radiation Oncology Samsung Medical Center DBCG 82 b & c Overgaard et al Radiot Oncol 2007 1152 pln(+), 8 or more nodes removed Systemic
More informationProphylactic Mastectomy State of the Art
Memorial Sloan-Kettering Cancer Center 1275 York Avenue, New York, NY 10065 6 th Brazilian Breast Cancer Conference Sao Paulo, Brazil 9 March 2012 Prophylactic Mastectomy State of the Art Monica Morrow
More informationLecture 5. Primary systemic therapy: clinical and biological endpoints
Lecture 5 Primary systemic therapy: clinical and biological endpoints Valentina Guarneri, M.D., Ph.D. Primary systemic therapy in breast cancer Firstly introduced d into clinical i l practice in 70s for
More informationLoco-Regional Management After Neoadjuvant Chemotherapy
1 Loco-Regional Management After Neoadjuvant Chemotherapy Terry Mamounas, M.D., M.P.H., F.A.C.S. Medical Director, Comprehensive Breast Program UF Health Cancer Center at Orlando Health Professor of Surgery,
More informationIs Breast Radiation Therapy Necessary in the Elderly? Cancer and Leukemia Group B Radiation Therapy Oncology Group Eastern Cooperative Oncology Group
Is Breast Radiation Therapy Necessary in the Elderly? Cancer and Leukemia Group B Radiation Therapy Oncology Group Eastern Cooperative Oncology Group CALGB 9343 Submitted 1990 Opened July 15, 1994 Closed
More information2017 Quality and Outcomes Report
217 Quality and Outcomes Report TABLE OF CONTENTS Quality Review page 2 Quality Accreditations page 2 Quality Measures page 4 Quality Improvements page 6 Community Outreach Activities and Outcomes page
More informationCertified Breast Care Nurse (CBCN ) Test Content Outline (Effective 2018)
Certified Breast Care Nurse (CBCN ) Test Content Outline (Effective 2018) I. Coordination of Care - 26% A. Breast health, screening, early detection, risk assessment and reduction 1. Issues related to
More information2008 Cancer Committee
2008 Cancer Committee Breast Cancer Study Stages I-III Ina Stafford, CTR JoAnne Schahuber, RT(R) (T) (M) (QM) Table of Cont ent s Table of Contents... 1 Breast Cancer Facts.. 2 CoxHealth Cancer Committee
More informationPatterns of Care in Patients with Cervical Cancer:
Patterns of Care in Patients with Cervical Cancer: Power and Pitfalls of Claims-Based Analysis Grace Smith, MD, PhD, MPH Resident, PGY-5 Department of Radiation Oncology, MD Anderson Cancer Center Acknowledgments
More informationExceptional cancer care, close to home.
Exceptional care, close home. 2017 Annual Reptg Outcomes 1 Permance Measures Surgery not first treatment certa lung s Measure: Surgery not first treatment course cn2, M0 lung cases outcomes: permance rate
More informationMemorialCare Breast Center at Long Beach Medical Center
MemorialCare Breast Center at Long Beach Medical Center 2017 ANNUAL REPORT 562.933.7880 memorialcare.org/lbbreast Todd Cancer Pavillion, 2 nd Floor 2810 Long Beach Blvd. Long Beach, CA 90806 The MemorialCare
More informationLoco-Regional Management After Neoadjuvant Chemotherapy
1 Loco-Regional Management After Neoadjuvant Chemotherapy Terry Mamounas, M.D., M.P.H., F.A.C.S. Medical Director, Comprehensive Breast Program UF Health Cancer Center at Orlando Health Professor of Surgery,
More informationBreast cancer (screening) in older individuals: the oncologist s viewpoint for the geriatrician
Breast cancer (screening) in older individuals: the oncologist s viewpoint for the geriatrician Hans Wildiers Medical oncologist, Leuven, Belgium Past chairman of the EORTC elderly task force President-elect
More information